Forum Topic News
  • Conversation: FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

    • February 1, 2019 11:40 AM GMT
      • Post(s)
        621

      FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the F...

      Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA® (pemetrexed for injection) in combination with KEYTRUDA® (pembrolizumab), developed and marketed by Merck (known as MSD outside the U.S. and Canada), and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is approved based on data from Merck's Phase 3 KEYNOTE-189 trial, which enrolled patients regardless of PD-L1 expression and had dual primary endpoints of overall survival (OS) and progression-free survival (PFS).
      Read more: https://prn.to/2MIngRa
      Stay updated with the latest:
      PharmeMed: https://www.pharmemed.com
      LinkedIn: https://www.linkedin.com/company/pharmemed/
      Twitter: https://twitter.com/PharmaJob
      #fda #chemotherapy #cancer #pharmaceutical #healthcare #medical #lungcancer

Add Reputation

Do you want to add reputation for this member by this post?

or cancel